Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-Current DebtShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Net Income: 2014-2025

Historic Net Income for Ascendis Pharma A (ASND) over the last 12 years, with Sep 2025 value amounting to -$62.8 million.

  • Ascendis Pharma A's Net Income rose 41.10% to -$62.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$236.4 million, marking a year-over-year increase of 47.15%. This contributed to the annual value of -$409.2 million for FY2024, which is 21.00% up from last year.
  • Latest data reveals that Ascendis Pharma A reported Net Income of -$62.8 million as of Q3 2025, which was down 78.17% from -$35.3 million recorded in Q2 2025.
  • Ascendis Pharma A's Net Income's 5-year high stood at -$35.3 million during Q2 2025, with a 5-year trough of -$200.7 million in Q4 2022.
  • For the 3-year period, Ascendis Pharma A's Net Income averaged around -$101.0 million, with its median value being -$106.7 million (2024).
  • Its Net Income has fluctuated over the past 5 years, first tumbled by 85.96% in 2022, then skyrocketed by 69.93% in 2025.
  • Ascendis Pharma A's Net Income (Quarterly) stood at -$121.3 million in 2021, then tumbled by 65.42% to -$200.7 million in 2022, then surged by 59.64% to -$81.0 million in 2023, then soared by 52.12% to -$38.8 million in 2024, then surged by 41.10% to -$62.8 million in 2025.
  • Its last three reported values are -$62.8 million in Q3 2025, -$35.3 million for Q2 2025, and -$99.5 million during Q1 2025.